Skip to main content


RheumThoughts are opinion pieces from healthcare professionals in the RheumNow network. They are not indicative of the views and opinions of the RheumNow Editorial team. To join the discussion on this article, use the discussion area below.

Want to submit your own RheumThoughts?

RheumThoughts: Obesity and Lupus: Coconspirator or Comorbidity?

alfred.hj.kim@gmail.com
Sep 09, 2026 8:00 am

Dr. Al Kim, St. Louis, discusses the effects of obesity on lupus activity, organ damage, complement levels and mTor activation.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Dr. Kim is an Associate Professor of Medicine at Washington University School of Medicine, where he directs the Lupus Center (founded in 2013). He also leads the Biobanking and Phenotyping Core within the NIH/NIAMS P30-funded Rheumatic Diseases Research Resource-based Center and is a Faculty Scholar at the Institute of Public Health. In addition, he serves as the Associate Program Director for the Rheumatology Fellowship Program at Washington University and is Chief Medical Officer at Kypha, Inc., an innate immune diagnostics company.

His research group focuses on translational and clinical investigations of systemic lupus erythematosus (SLE), including examining the utility of complement activation products as both biomarkers of SLE disease activity and drivers of disease progression, evaluating state-of-the-art noninvasive imaging platforms (such as photoacoustics) to detect lupus nephritis without the need for biopsy, and addressing healthcare disparities in SLE by investigating the factors that contribute to these gaps and how they affect patient outcomes. Dr. Kim serves as Chair of the Impact Advisory Council, a member of the Executive Council, and a member of the Board of Directors at the Rheumatology Research Foundation. He is a core member of the OMERACT SLE Working Group and co-chair of the Biomarker Roadmap Committee. 


 

×